Related Experiment Video
Updated: Jun 4, 2026
09:01
Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach
Published on: June 5, 2010
Our experience on Actovegin, is it cutting edge?
P Lee1, A Rattenberry, S Connelly
1Cardiff University, Institute of Medical Engineering and Medical Physics, Cardiff, United Kingdom. paul@medwales.com
International Journal of Sports Medicine
|January 29, 2011
Summary
Actovegin may accelerate recovery for athletes with muscle injuries, allowing them to return to play 8 days sooner than with physiotherapy alone. This pilot study found no adverse reactions to Actovegin in treated athletes.
Area of Science:
- Sports Medicine
- Muscle Injury Research
- Pharmacology
Background:
- Muscle injuries are prevalent in sports, causing significant training and match loss.
- Actovegin (deproteinised extract) use in sports medicine is controversial, with anecdotal claims of performance enhancement.
- Limited scientific understanding exists regarding Actovegin's effects on muscle injury recovery.
Purpose of the Study:
- To review current evidence on Actovegin's efficacy and legal status in sports.
- To investigate Actovegin's potential role in treating sports-related muscle injuries.
- To report findings from a pilot study on Actovegin treatment for muscle injuries.
Main Methods:
- Literature review of Actovegin's evidence and regulatory standing.
- Pilot study involving athletes with muscle injuries, comparing Actovegin treatment to physiotherapy alone.
- Data collection on return-to-play timelines and adverse events.
Main Results:
- Athletes receiving Actovegin treatment returned to play an average of 8 days earlier than those receiving physiotherapy alone (p=0.033).
- The study observed no adverse reactions in participants treated with Actovegin.
- Current evidence on Actovegin's performance-enhancing capacity is limited, despite its long history of use.
Conclusions:
- Actovegin shows potential as an adjunct therapy for accelerating muscle injury recovery in athletes.
- Further research is warranted to elucidate Actovegin's mechanism of action and confirm its efficacy.
- The safety profile of Actovegin in this pilot study was favorable, with no reported adverse effects.
More Related Videos
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:16Vascular Spasm
The vascular phase, also known as vasospasm, is the initial stage of hemostasis, crucial for preventing excessive bleeding when a blood vessel is injured. After a vessel is cut, nerves in the damaged area trigger pain and other sensory impulses. Simultaneously, the smooth muscles in the vessel wall contract, resulting in a vascular spasm. This contraction reduces the vessel's diameter at the injury site, slowing or stopping blood loss through the vessel wall. Vascular spasms typically last for...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:26Varicose Veins I: Introduction
Varicose veins, or varicosities, are abnormally dilated and twisted superficial veins caused by venous valve incompetence. This condition commonly affects the lower extremities, especially the saphenous veins, due to the higher pressure from prolonged standing and walking. However, varicosities can also occur in other areas, such as the esophagus, vulva, spermatic cords, and anorectal region.Etiology and typesPrimary varicose veins, often idiopathic, are more common in women due to inherent...
01:23Tissue Renewal without Stem Cells
After cellular or tissue damage, the resident stem cells present in the human body can locally repair and regenerate the damaged tissue or organ. However, even though some tissues do not have stem cells, they can repair and regenerate with the help of pre-existing cells. For example, beta cells of the pancreas and hepatocytes of the liver can divide to renew and regenerate the tissue. Here, both cell division and cell death are well regulated by homeostasis.
However, failure of such a system...
However, failure of such a system...
01:26Pharmaceutical Equivalents
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.